Nearly two-thirds of patients treated for colorectal cancer reported some measure of financial burden due to their treatment, according to a new study from researchers at the University of Michigan Comprehensive Cancer Center. The burden was greatest among patients who received chemotherapy and among younger patients who worked in low-paying jobs.
The study surveyed 956 patients who had been treated for stage 3 colorectal cancer. Among this group, chemotherapy is known to increase survival by up to 20 percent and is routinely recommended following surgery.
READ FULL ARTICLE From Medical Express